Skye Bioscience, Inc. — Investor Relations & Filings

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for obesity and other metabolic diseases. The company's strategy involves advancing first-in-class molecules that modulate G-protein coupled receptors (GPCRs). Its lead drug candidate, nimacimab, is a peripherally-acting antibody that inhibits the cannabinoid receptor 1 (CB1). Nimacimab is designed to target CB1 receptors in peripheral tissues like adipose, liver, and muscle, with the goal of reducing hunger and increasing energy expenditure while limiting central nervous system exposure. This mechanism is being investigated for its potential as a complementary approach to existing obesity therapies, aiming to provide more sustainable weight loss, improved body composition, and better tolerability. Nimacimab is being evaluated in Phase 2 clinical trials.